Clinical trial

Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

NCT06976944

Study summary

ClinicalTrials.gov

Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxel View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Bevacizumab Normalized identity: bevacizumab View linked drug · Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-06-24

PhasePHASE2

Conditions

Recurrent Triple-Negative Breast Cancerunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

PaclitaxelDRUG · verified · RxNorm: paclitaxel

BevacizumabDRUG · verified · RxNorm: bevacizumab

Sponsors & collaborators

Yukinori Ozakilead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

NagoyaAichi-ken, Japan3 OsakaOsaka, Japan2 SapporoHokkaido, Japan1 HiroshimaHiroshima, Japan1 OkayamaOkayama-ken, Japan1 GifuGifu, Japan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06976944 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.